Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Vatreptacog alfa (Primary)
- Indications Haemophilia
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors Novo Nordisk
- 21 Apr 2016 Status changed from recruiting to completed.
- 10 Nov 2015 Planned number of patients changed from 25 to 24 as reported by ClinicalTrials.gov record.
- 07 Sep 2015 New trial record